Soligenix Announces Positive Clinical Results from Compatibility Study of HyBryte(TM) in the Treatment of Cutaneous T-Cell Lymphoma
Results Confirm and Extend Response Results from Phase 3 FLASH Study PRINCETON, N.J., May 4, 2023 -- (Healthcare Sales & Marketing Network) -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on ... Biopharmaceuticals, Oncology Soligenix, HyBryte, synthetic hypericin, photodynamic therapy, CTCL (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 4, 2023 Category: Pharmaceuticals Source Type: news

Soligenix Receives Refusal to File Letter from U.S. FDA for HyBryte(TM) New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma
Soligenix intends to seek guidance from the FDA on how to further advance HyBryte™ towards potential approval PRINCETON, N.J., Feb. 14, 2023 -- (Healthcare Sales & Marketing Network) -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-... Biopharmaceuticals, Oncology, FDA Soligenix, HyBryte, synthetic hypericin, photodynamic therapy, CTCL (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 14, 2023 Category: Pharmaceuticals Source Type: news

Extracorporeal Photopheresis and Its Use in Dermatology Extracorporeal Photopheresis and Its Use in Dermatology
While cutaneous T-cell lymphoma remains the only FDA approved use of extracorporeal photopheresis, it has potential as an off-label treatment for numerous dermatological conditions.Skin Therapy Letter (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 18, 2023 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

Results of Novel Clinical Study of Guselkumab and Golimumab Combination Therapy Show Adults with Moderately to Severely Active Ulcerative Colitis Maintained Higher Rates of Clinical, Histologic, and Endoscopic Remission at Week 38
SPRING HOUSE, PENNSYLVANIA, October 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from an ongoing analysis of a Phase 2a clinical trial showing adults with moderately to severely active ulcerative colitis (UC) who received 12 weeks of combination induction therapy with guselkumab and golimumab, followed by a transition to guselkumab alone for maintenance, achieved a clinical remission ratea (based on the modified Mayo score [mMayo])b at week 38 of 47.9 percent, a higher rate than induction and maintenance treatment with either guselkumab alone (31.0 percent) or golimumab al...
Source: Johnson and Johnson - October 10, 2022 Category: Pharmaceuticals Source Type: news

Incidence of Cutaneous T - Cell Lymphoma Up in the U.S.
Overall incidence rate six times higher for patients aged 40 years or older versus younger than 40 years, but increase in CTCL rate significantly higher for those younger than 40 years (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 13, 2022 Category: Cancer & Oncology Tags: Internal Medicine, Oncology, Pathology, Journal, Source Type: news

Incidence of Cutaneous T-Cell Lymphoma Up in the U.S.
TUESDAY, Sept. 13, 2022 -- The overall incidence of cutaneous T-cell lymphoma (CTCL) increased in the United States from 2000 to 2018, according to a research letter published online Sept. 1 in JAMA Oncology. Zhuo Ran Cai, M.D., from Stanford... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 13, 2022 Category: Pharmaceuticals Source Type: news

What Caused This Summer Birthday Party Rash?
Discussion Panniculitides are a diverse group of problems involving inflammation of subcutaneous fat. Subcutaneous fat has limited ability to show different patterns of disease and therefore the clinical appearance is the same but has different etiologies. The skin appears red or purple, swollen, may have discrete nodule(s) or plaque(s) and the affected area can be painful or pruritic. If necessary skin biopsy can help determine the etiology. Overall panniculitides are not very common but some presentations are expected because of particular exposure (i.e. cold) or inflammatory disease processes. Types of panniculitides in...
Source: PediatricEducation.org - August 22, 2022 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Michael Girardi appointed Evans Professor of Dermatology
Girardi is an internationally recognized investigator and translational expert in the advancement of personalized therapy for cutaneous T cell lymphoma. (Source: Yale Science and Health News)
Source: Yale Science and Health News - June 21, 2022 Category: Universities & Medical Training Source Type: news

Dialectic Therapeutics Announces DT2216 Has Received Orphan Drug Designation from the FDA for the Treatment of T-Cell Lymphoma
DALLAS, March 14, 2022 -- (Healthcare Sales & Marketing Network) -- Dialectic Therapeutics, Inc. (Dialectic®), a Texas-based clinical stage biotechnology company focused on creating innovative new technologies to treat cancer, today announced that the... Biopharmaceuticals, Oncology, FDA Dialectic Therapeutics, APTaD, DT2216, T-cell lymphoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 14, 2022 Category: Pharmaceuticals Source Type: news

Secura Bio Announces Copiktra (duvelisib) Strategic Focus On T-cell Lymphoma And Voluntary U.S. Withdrawal Of The Relapsed Or Refractory Follicular Lymphoma Indication
SUMMERLIN, Nev., Dec. 3, 2021 /PRNewswire/ -- Secura Bio, Inc. (Secura Bio) - (www.securabio.com), an integrated pharmaceutical company dedicated to the worldwide development and commercialization of impactful oncology therapies, has voluntarily... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - December 3, 2021 Category: Drugs & Pharmacology Source Type: news

New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Dr Reddy's inks pact with Citius Pharma to sell all rights to anti-cancer agent E7777
Dr Reddy's will receive $ 40 million upfront upon the closing of the transaction, followed by approval milestone payment of up to $40 million related to the cutaneous T-cell lymphoma indication approval and up to $70 million for additional indication approvals. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - September 4, 2021 Category: Pharmaceuticals Source Type: news

How I Diagnose Angioimmunoblastic T-Cell Lymphoma How I Diagnose Angioimmunoblastic T-Cell Lymphoma
Diagnosis of angioimmunoblastic T-cell lymphoma is challenging due to its wide clinical and histopathologic spectrum. Review its pathologic features and a path to accurate diagnosis in this paper.American Journal of Clinical Pathology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 8, 2021 Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news

Stem Cell Transplant Reviewed for Peripheral T - Cell Lymphoma
Three - and five - year overall survival similar with allogeneic or autologous HSCT, but transplant - related mortality higher with allogeneic HSCT (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - June 10, 2021 Category: Cancer & Oncology Tags: Oncology, Pathology, Journal, Source Type: news

Stem Cell Transplant Reviewed for Peripheral T-Cell Lymphoma
THURSDAY, June 10, 2021 -- For patients with refractory or relapsed peripheral T-cell lymphoma (R/R-PTCL), three- and five-year overall survival (OS) and progression-free survival (PFS) are similar with allogeneic or autologous hematopoietic stem... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 10, 2021 Category: Pharmaceuticals Source Type: news